Compare Amgen, Inc. (AMGN) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Kraft Heinz Co — how do they compare? Amgen, Inc. trades at $413.59 (market cap $224.14B), while Kraft Heinz Co trades at $24.25 (market cap $29.23B). The key difference: Amgen, Inc. is far larger — about 7.7× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.49%). Which is the better fit depends on your goals.
| AMGN | KHC | |
|---|---|---|
Market Cap | $224.14B | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $417.20 | $28.06 |
52-Week Low | $271.18 | $21.21 |
Enterprise Value | $267.45B | $45.55B |
Dividend Yield | 2.43% | 6.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Kraft Heinz (KHC) trades at $24.93, down 1.54% on the day, with a bearish technical signal and mixed fundamentals. The company reported three consecutive quarterly earnings beats but faces profitability challenges with a negative net income margin of -13.64% and ROE of -8.78%. Recent news highlights CEO Steve Cahillane's turnaround strategy with increased marketing investments, while analysts remain cautious with only 11.43% buy ratings.
The stock presents a value opportunity with attractive valuation ratios (P/E 13.04, P/B 0.81) and 6.4% dividend yield, but significant risks include ongoing earnings erosion, competitive pressures, and high debt levels. The consensus price target of $24.00 suggests limited upside from current levels, requiring careful monitoring of the company's execution on its growth strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
